# EDGAR Filing Document

**Accession Number:** 0001445283
**File Stem:** 0001193125-23-076235
**Filing Date:** 2023-3
**Character Count:** 12351
**Document Hash:** 8d3ce4615412af4d37b22d8edc830fd2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-076235.hdr.sgml**: 20230322

**ACCESSION NUMBER**: 0001193125-23-076235

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230322

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230322

**DATE AS OF CHANGE**: 20230322

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KINETA, INC./DE
- **CENTRAL INDEX KEY:** 0001445283
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37695
- **FILM NUMBER:** 23751239

**BUSINESS ADDRESS:**
- **STREET 1:** 219 TERRY AVE. N.
- **STREET 2:** SUITE 300
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109
- **BUSINESS PHONE:** (206) 378-0400

**MAIL ADDRESS:**
- **STREET 1:** 219 TERRY AVE. N.
- **STREET 2:** SUITE 300
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YUMANITY THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20201223

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROTEOSTASIS THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20140813

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROTEOSTASIS THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080916

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of report (Date of earliest event reported): March 22, 2023

------

## KINETA, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37695** | **20-8436652** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer<br>Identification No.)** |

---

---

| | |
|:---|:---|
| **219 Terry Ave. N., Suite 300**<br> **Seattle, WA** | **98109** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

#### Registrant's telephone number, including area code: (206) 378-0400

#### N/A

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of exchange**<br> **on which registered** |
| Common Stock, par value $0.001 per share KA | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 7.01.** | **Regulation FD Disclosure.**  |

---

On March 22, 2023, Kineta, Inc. issued a press release announcing that its Chief Scientific Officer, Thierry Guillaudeux, Ph.D., will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held onsite in Orlando, Florida on April 14-19, 2023. Dr. Guillaudeux will give a poster presentation highlighting new preclinical data on VISTA expression as a potential biomarker in patients with advanced solid tumors. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01.** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| 99.1 | [Press Release, dated March 22, 2023.](d413566dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 22, 2023 | **Kineta, Inc.** | **Kineta, Inc.** |
|  | By: | /s/ Shawn Iadonato |
|  | Name: | Shawn Iadonato, Ph.D. |
|  | Title: | Chief Executive Officer and Director |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g413566g0321232314170.jpg)

**Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023** 

SEATTLE, March 22, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that the company will present its VISTA clinical program at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held onsite in Orlando, Florida on April 14-19, 2023. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will give a poster presentation highlighting new preclinical data on VISTA expression as a potential biomarker in patients with advanced solid tumors.

**<u>Presentation Details:</u>**

**Poster Title:** VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial

**Abstract Number:** 972

**Session Title:** Biomarkers of Therapeutic Benefit 1

**Session Date and Time:** Sunday, April 16, 2023 at 1:30 P.M. - 5:00 P.M. Eastern Time

**Location:** Section 39

**About Kineta** 

Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients' lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta, please visit <u>www.kinetabio.com</u>, and follow Kineta on <u>Twitter</u>, <u>LinkedIn</u> and <u>Facebook</u>.

KVA12123 (formerly referred to as KVA12.1) is expected to be a differentiated VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12123 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian. These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12123.

------

![LOGO](g413566g0321232314170.jpg)

**Cautionary Statements Regarding Forward-Looking Statements** 

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: Kineta's plans for pre-clinical and clinical studies and projected timelines for the initiation and completion of pre-clinical and clinical trials and other activities; regulatory filings for its product candidates; investor returns; anticipated drug effects in human subjects; and other statements that are not historical in nature. The use of words such as, but not limited to, "believe," "expect," "estimate," "project," "intend," "future," "potential," "continue," "may," "might," "plan," "will," "should," "seek," "anticipate," or "could" and other similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Kineta's current beliefs, expectations and assumptions regarding the future of Kineta's business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Such forward-looking statements are subject to a number of material risks and uncertainties including, but not limited to: the adequacy of Kineta's capital to support its future operations (including its ability to complete the second tranche of the previously disclosed contemplated private placement in the first quarter of 2023) and its ability to successfully initiate and complete clinical trials; the difficulty in predicting the time and cost of development of Kineta's product candidates; Kineta's plans to research, develop and commercialize its current and future product candidates, including, but not limited to, KVA12123; the timing and anticipated results of Kineta's planned pre-clinical studies and clinical trials and the risk that the results of Kineta's pre-clinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials; the timing of the availability of data from Kineta's clinical trials; the timing of any planned investigational new drug application or new drug application; the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta's product candidates; Kineta's commercialization, marketing and manufacturing capabilities and strategy; Kineta's ability to identify additional product candidates with significant commercial potential and to expand its pipeline of potential novel immunotherapies for cancer patients; developments and projections relating to Kineta's competitors and its industry; the impact of government laws and regulations; the impact of public health epidemics affecting countries or regions in which Kineta has operations or does business,

------

![LOGO](g413566g0321232314170.jpg)

such as the COVID-19 pandemic; the timing and outcome of Kineta's planned interactions with regulatory authorities; Kineta's ability to protect its intellectual property position; Kineta's estimates regarding future revenue, expenses, capital requirements and need for additional financing; and those risks filed as an exhibit to Kineta's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on December 22, 2022, as well as discussions of potential risks, uncertainties and other important factors in Kineta's subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Except as required by law, Kineta undertakes no obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise.

**FOR FURTHER INFORMATION, PLEASE CONTACT:** 

**Kineta, Inc. :** 

Jacques Bouchy

EVP Investor Relations & Business Development

+1 206-378-0400

<u>jbouchy@kineta.us</u> 

**Investor Relations:** 

John Mullaly

LifeSci Advisors, LLC

<u>jmullaly@lifesciadvisors.com</u> 

Source: Kineta, Inc.

###